深圳市健翔生物制药

Shenzhen Jianxiang Biopharmaceutical is a Chinese biopharmaceutical company specializing in the formulation development, clinical sample preparation, and commercial-scale manufacturing of peptide therapeutics. Established in 2013 as a wholly-owned subsidiary of Shenzhen Jianyuan Pharmaceutical Technology (JYMed), the company operates as the formulation manufacturing arm of the group, while its sister company Hubei Jianxiang handles API production. Shenzhen Jianxiang features state-of-the-art, GMP-compliant production lines for cartridge injections, small-volume injections, and lyophilized powder injections, supporting both proprietary products and CDMO services. Its product portfolio and pipeline focus on high-demand peptide drugs, including semaglutide, tirzepatide, terlipressin, octreotide, and teriparatide. In November 2024, the company's parent, Shenzhen Jianyuan, was acquired by Sichuan Shuangma, integrating Shenzhen Jianxiang into a larger life sciences and CDMO growth platform.